Table 1 Characteristics of pediatric patients with drug-resistant epilepsy.

From: Healthcare utilization and costs after cranial epilepsy surgery and vagus nerve stimulation in pediatric drug-resistant epilepsy: a nationwide cohort study

 

Total (N = 6,020)

ASM–only (N = 5,407)

CES (N = 496)

VNS (N = 217)

P*

Sex

    

0.903

Male

3356 (55.8)

3009 (55.7)

224 (56.6)

123 (56.7)

 

Age at index date

    

< 0.001

< 4 year

2484 (41.3)

2223 (41.1)

193 (48.7)

68 (31.3)

 

4–11 year

1858 (30.9)

1640 (30.3)

124 (31.3)

94 (43.3)

 

12–18 year

1678 (27.9)

1544 (28.6)

79 (20.0)

55 (25.4)

 

Age at intervention

    

< 0.001

< 4 year

125 (20.6)

120 (30.7)

5 (2.3)

 

4–11 year

259 (42.6)

162 (41.4)

97 (44.7)

 

12–18 year

156 (25.7)

75 (19.2)

81 (37.3)

 

≥ 18 year

68 (11.2)

34 (8.7)

34 (15.7)

 

Insurance

    

0.007

National Health Insurance

5453 (90.6)

4877 (90.2)

375 (94.7)

201 (94.9)

 

Medical aid

567 (9.4)

530 (9.8)

21 (5.3)

23 (5.1)

 

Comorbidity and underlying disease

I. Certain infectious and parasitic disease

5331

4765 (88.1)

366 (92.4)

200 (92.2)

0.008

II. Neoplasms

833

691 (12.8)

107 (27.0)

35 (16.1)

< 0.00

III. Disease of the blood and blood-forming organs and certain disorders involving the immune mechanism

2367

2124 (39.3)

155 (39.1)

88 (40.6)

0.93

IV. Endocrine, nutritional, and metabolic diseases

4435

3991 (73.8)

278 (70.2)

166 (76.5)

0.18

V. Mental and behavioral disorders

3786

3383 (62.6)

247 (62.4)

156 (71.9)

0.02

VI. Diseases of the nervous system

3788

3381 (62.5)

246 (62.1)

161 (74.2)

0.002

VII. Diseases of the eye and adnexa

4994

4446 (82.2)

357 (90.2)

191 (88.0)

< 0.001

VIII. Diseases of the ear and mastoid process

3934

3505 (64.8)

279 (70.5)

150 (69.1)

0.04

IX. Diseases of circulatory system

2057

1842 (34.1)

135 (34.1)

80 (36.9)

0.7

X. Diseases of the respiratory system

5942

5331 (98.6)

394 (99.5)

217 (100.0)

0.07

XI. Diseases of the digestive system

5759

5156 (95.4)

386 (97.5)

217 (100.0)

< 0.001

XII. Diseases of the skin and subcutaneous tissue

5386

4809 (88.9)

366 (92.4)

211 (97.2)

< 0.001

XIII. Diseases of the musculoskeletal system and connective tissue

4685

4180 (77.3)

314 (79.3)

191 (88.0)

< 0.001

XIV. Diseases of the genitourinary system

3042

2703 (50.0)

205 (51.8)

134 (61.8)

0.003

XV. Pregnancy, childbirth, and the puerperium

41

38 (0.7)

3 (0.8)

0 (0.0)

0.55

XVI. Certain conditions originating in the perinatal period

839

796 (14.7)

26 (6.6)

17 (7.8)

< 0.001

XVII. Congenital malformations, deformations, and chromosomal abnormalities

1676

1441 (26.7)

181 (45.7)

54 (24.9)

< 0.001

XVIII. Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified

5781

5187 (95.9)

380 (96.0)

214 (98.6)

0.14

XIX. Injury, poisoning, and certain other consequences of external causes

4920

4375 (80.9)

346 (87.4)

199 (91.7)

< 0.001

XX. External causes of morbidity and mortality

149

128 (2.4)

13 (3.3)

8 (3.7)

0.27

XXI. Factors influencing health status and contact with health services

4554

4034 (74.6)

331 (83.6)

189 (87.1)

< 0.001

XXII. Codes for special purposes

130

119 (2.2)

5 (1.3)

6 (2.8)

0.35

  1. Values are presented as numbers (%). Its percentages represent the proportions of the total patient cohort. Disease categories followed the International Classification of Diseases (ICD-10) coding system.
  2. *P-values were calculated using the chi-square test. ASM, antiseizure medication; VNS, vagus nerve stimulation.